MedTrace Logo

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

NCT00330551 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2023-03-01

Study results available
· View outcomes & findings →

Summary

This study will determine the effectiveness of oral risperidone versus long-acting injectable risperidone in treating people with first-episode schizophrenia.

Conditions

Interventions

DRUG

Oral Risperidone

Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.

DRUG

Risperidone in Long-Acting Injectable Form (Consta)

Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.

Sponsors & Collaborators

Principal Investigators

  • Keith H. Nuechterlein, PhD · University of California, Los Angeles, Department of Psychiatry and Biobehavioral Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00330551 on ClinicalTrials.gov